Spectrum Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of Allos Therapeutics for $206 million upfront, plus a Contingent Value Right (CVR) entitling Allos to an additional payment if certain European regulatory and commercialization milestones for Folotyn are met. Folotyn (pralatrexate injection) is a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The drug generated more than $...